REG - ReNeuron Group plc - Result of AGM

ReNeuronAnnouncement

12/09/2019 11:25

RNS Number : 1409M
ReNeuron Group plc
12 September 2019
 


 
 



12 September 2019


AIM: RENE



 
 
ReNeuron Group plc
("ReNeuron" or the "Company")
 
Result of AGM
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that all resolutions put to shareholders at its Annual General Meeting ("AGM") held earlier today were duly passed.
 
ENDS
 
ENQUIRIES:
 



ReNeuron


 +44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer








 
Buchanan (UK)


 
+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham








 
Argot Partners (US)
Stephanie Marks, Claudia Styslinger
 
Stifel Nicolaus Europe Limited


     
  +1 212 600 1902
        
 
 +44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)








 
N+1 Singer


 
+44 (0) 20 7496 3000




Aubrey Powell, James Moat, Mia Gardner
(Joint Broker)







 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGCKBDDKBKDFCD